Navigation Links
Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System
Date:8/23/2010

MINNEAPOLIS, Aug. 23 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Noridian Administrative Services, LLC and Palmetto GBA, South Carolina, both regional Medicare carriers, now cover percutaneous, posterior tibial nerve stimulation (PTNS) using the Urgent® PC Neuromodulation System for the treatment of the symptoms of overactive bladder.  Noridian administers benefits for Medicare beneficiaries in North and South Dakota, Montana, Wyoming, Utah and Arizona.  The Palmetto GBA policy covers Medicare beneficiaries in South Carolina.

Both Noridian and Palmetto GBA will cover PTNS therapy for patients who have failed, or demonstrated intolerance to, the standard anticholinergic drug therapy.  Coverage includes an initial course of 12 weekly PTNS treatments, and for those patients who respond to the initial PTNS treatments, additional treatments once every three weeks for up to one year.  Claims for PTNS treatments can be billed electronically using the unlisted CPT code 64999.  In addition, Noridian has indicated that up to three physician consultations to evaluate and manage treatments during the initial course of PTNS therapy will also be reimbursed.

"We are very pleased and excited that these two regional Medicare carriers now cover PTNS treatments using our Urgent PC Neuromodulation System," said David Kaysen, President and CEO of Uroplasty, Inc.  "Both carriers have reviewed our strong clinical data and determined that PTNS treatments should be covered and reimbursed for the beneficiaries within their coverage areas.  We are continuing to actively meet with medical directors of other Medicare carriers and private payers to share with them the strong clinical data and encourage them to cover and reimburse PTNS treatments."

Links to the websites providing details on the coverage policies of the two Medicare carriers are as follows:

For Noridian:

https://www.noridianmedicare.com/provider/updates/docs/PTNS_Coverage_acro.pdf

For Palmetto GBA:  http://www.cms.gov/mcd/viewlcd_pdf.asp?lcd_id=27267&lcd_version=10&contractor_id=19

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements. For Further Information: Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer

952.426.6140

EVC Group

Doug Sherk (Investors)

415.896.6820

Chris Gale (Media)

646.201.5431
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
5. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
6. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
7. Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews
8. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
9. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
10. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
11. WJB Capital Group, Inc. Expands Coverage of Healthcare Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):